Compare VanEck Australian Floating Rate ETF (FLOT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Novartis AG — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while VanEck Australian Floating Rate ETF pays none, and Novartis AG is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| FLOT | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $168.62 |
52-Week Low | $50.72 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT, the iShares Floating Rate Bond ETF, trades at $50.93, showing minimal daily movement. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights its role as a potential hedge against rising interest rates, with a focus on high credit quality and a 4.0% SEC yield. Dividend payments are consistent, with recent distributions around $0.17-$0.18 per share.
The outlook for FLOT is cautiously positive if the Federal Reserve raises rates, as its floating rate structure could benefit income growth. Risks include credit quality deterioration and persistent inflation without Fed action. Analyst sentiment is generally neutral, viewing it as a stable short-term cash alternative rather than a growth vehicle.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
